Saturday 17 October 2026
Export NRSN’s income statement to Excel — free account
NeuroSense Therapeutics Ltd.
NRSN Healthcare Biotechnology
Insiders bought in the last twelve months.
3.07
0.10
−3.15%
Follow NRSN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.31 | 2.21 | 0.84 | 4.28 | 19.12 | 6.38 | 24.68 | — |
Net Debt/EBITDA |
0.01 | 0.35 | 0.22 | 0.52 | 1.99 | 0.26 | 0.72 | — |
Debt/Assets |
7.00% | 0.00% | 2.29% | 1.91% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.05) | 0.00 | (0.04) | 0.03 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.69 | 0.99 | 0.83 | 0.61 | 0.38 | 0.25 | 0.48 | — |
Capex/Depreciation |
(0.50) | (0.14) | (1.38) | (0.79) | (5.67) | (3.00) | 0.00 | — |
Interest Coverage |
— | — | (5.45) | (301.16) | (4.71) | (2,888.00) | (247.00) | — |
| (2,174.98%) | (2,478.16%) | (523.68%) | (168.75%) | (83.62%) | (358.66%) | 0.00% | — | |
| (397.11%) | (263.14%) | (185.53%) | (128.94%) | (66.19%) | (326.18%) | (255.92%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (3,355.98%) | — |
Return on Tangible Assets |
662.20% | (412.36%) | 2,206.77% | (215.28%) | (37.30%) | (429.14%) | (138.39%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(6.03) | (10.90) | (12.29) | (13.31) | (4.98) | (2.55) | (2.54) | — |
Cash per Share |
0.17 | 3.67 | 3.93 | 12.39 | 35.56 | 2.67 | 3.86 | — |
Shareholders Equity per Share |
(1.22) | 2.78 | (2.58) | 9.77 | 28.85 | 2.39 | 3.96 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(1.22) | 2.78 | (2.58) | 9.77 | 28.85 | 2.39 | 3.96 | — |
Free Cash Flow |
(7.68) | (10.14) | (8.38) | (7.66) | (1.56) | (0.70) | (0.59) | — |
Working Capital |
(1.74) | 2.41 | (0.54) | 5.66 | 10.82 | 0.65 | 0.88 | — |
Capital Expenditures |
(0.01) | 0.00 | (0.03) | (0.07) | (0.02) | (0.01) | (0.01) | — |
Net Current Asset Value |
(1.81) | 2.41 | (2.03) | 5.29 | 8.99 | 0.65 | 0.88 | — |
| Other line items | ||||||||
Quick Ratio |
0.31 | 2.21 | 0.84 | 4.28 | 19.12 | 6.38 | 24.68 | — |
Depreciation/Fixed assets |
0.28 | 0.33 | 0.25 | 1.16 | 0.16 | 0.23 | 0.00 | — |
Cash ROIC |
602.27% | (169.08%) | (843.36%) | (59.39%) | (7.74%) | (50.47%) | (32.49%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(6.02) | (10.90) | (12.25) | (13.19) | (4.93) | (2.52) | (2.51) | — |
Capex per Share |
(0.01) | 0.00 | (0.04) | (0.12) | (0.05) | (0.03) | (0.03) | — |
Average Receivables |
0.78 | 0.61 | 0.25 | 0.28 | 0.17 | 0.02 | — | — |
Average Payables |
0.98 | 1.31 | 0.98 | 0.27 | 0.05 | 0.04 | — | — |
Average Assets |
2.80 | 3.88 | 5.45 | 9.57 | 6.11 | 0.87 | 0.48 | — |
Average Common Equity |
0.51 | 0.41 | 1.93 | 7.31 | 4.83 | 0.79 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026